Incentives

Modeling the value of an effective antibiotic — Megiddo et al.

Dear All: I have previously written about the challenge of applying health technology assessment (HTA) to estimate the monetary value of an effective antibiotic: To my knowledge, the most detailed attempt to estimate the value of antibiotic was in 2014 by Sertkaya et al.  In that analysis, the value that the developer might receive through sales ranged from -$5 to +$40m across six

Read More »

Let’s make a pull incentive happen in the US during the 116th Congress!

Dear All: I’ve written a lot about the need for pull incentives, preferably delinked (some papers to read, comments by TATFAR, highlights from Davos 2018, and the UK commits to trying delinkage).  Now, I am delighted to report that a really serious effort is underway in the US to make something happen during the 116th Congress. The essential document can be

Read More »

Three $10k prizes for initiatives that improve access / create demand for diagnostics in LMICs

Dear All: Following the precept (often attributed to Osler, but I can’t find it in his Principles and Practice 1892) that the 3 core elements of treatment are “diagnosis, diagnosis, and diagnosis,” FIND (Foundation for Innovative New Diagnostics) is an international non-profit organization that enables the development and delivery of diagnostic tests for poverty-related diseases, including TB, malaria,

Read More »

PACCARB wants to hear from you! Deadline, 7 Jan 2019

Dear All: The US Presidential Advisory Council on Combating Antimicrobial Resistant Bacteria (PACCARB) has released a request for information (RFI) in which it seeks comments on priority actions for the future. Here is the link to the Federal Register notice: https://www.federalregister.gov/documents/2018/11/23/2018-25435/notice-of-request-for-information-a-notice-by-the-presidential-advisory-council-on-combating In brief, PACCARB has pursued these 5 goals from the first US National Action

Read More »

UK Antibiotic Subscription Pilot: Post-webinar FAQ document

Dear All, Kevin Outterson and I recently shared our analysis of the NICE/NHS England pilot of an antibiotic procurement subscription model (link to that newsletter). The NICE/NHS team have now released a post-webinar FAQ document. Here is the link to the document … and I’ve also added the link to the initial webpage (cited just above) discussing

Read More »

UK Antibiotic Subscription Pilot implies Pull Incentive of up to $4b across the G20

Note that there is a follow-up newsletter that covers a post-webinar FAQ. After reading this newsletter as introduction, please go here for the follow-up newsletter. Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), Prior newsletters have covered the antibiotic evaluation procurement pilot being run by NICE and NHS England (go here for the

Read More »

Send a note to your congressman/woman today!

Dear All, If you are a US citizen, you have an opportunity right now (as in today/tomorrow) to push for the inclusion of the DISARM Act in the COVID-19 bill(s) currently being circulated in Congress. As a reminder, DISARM is the legislation that would reimburse QIDP antimicrobials in the hospital setting outside of the DRG

Read More »

Tetraphase sold for $14m … and $600m goes up in smoke!

Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter): Wonkish and long note alert … top-up your coffee and settle in… We learned about a week ago that Tetraphase, despite having brought an antibacterial (eravacycline) to approval, has been sold for stock worth $14.4m (plus a potential $12.5m more if aggressive sales targets are achieved).

Read More »
Scroll to Top